Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes
Get Live Data
168.00    3.25 (1.97%)
Bid:
158.50
Ask:
167.50
Spread: 9.00 (5.678%)
Market Cap: £1.44b
HCM Live PriceLast checked at - London Stock Exchange

Intraday Hutchmed Share Chart

Hutchmed News

Hutchmed submits new drug application to US FDA for cancer treatment
31 Mar 2023

Hutchmed submits new drug application to US FDA for cancer treatment

(Alliance News) - Hutchmed (China) Ltd on Friday said it has completed the rolling submission of a new drug application for its fruquintinib cancer dr...

Hutchmed China inks global licensing deal with Takeda on fruquintinib
14 Mar 2023

Hutchmed China inks global licensing deal with Takeda on fruquintinib

(Alliance News) - Hutchmed China Ltd on Tuesday said it closed a license agreement with a subsidiary of Tokyo-based drug maker Takeda Pharmaceutical C...

DIRECTOR DEALINGS: Hutchmed CFO banks GBP4 million; Haleon chair buys
8 Mar 2023

DIRECTOR DEALINGS: Hutchmed CFO banks GBP4 million; Haleon chair buys

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Tuesday and Wednesday and...

Hutchmed expects revenue climb from oncology, immunology division
28 Feb 2023

Hutchmed expects revenue climb from oncology, immunology division

(Alliance News) - Hutchmed (China) Ltd expects a sharp rise in revenue from its oncology and immunology-focused arm, as the biopharmaceutical firm loo...

Hutchmed enrols last patient in lymphoma treatment trial
27 Feb 2023

Hutchmed enrols last patient in lymphoma treatment trial

(Sharecast News) - Hutchmed China announced the completion of patient enrollment in a phase two registration trial of 'amdizalisib' on Monday, for the...

Hutchmed completes patient enrolment for trial testing cancer therapy
27 Feb 2023

Hutchmed completes patient enrolment for trial testing cancer therapy

(Alliance News) - Hutchmed (China) Ltd on Monday said that it has completed patient enrolment for the Phase Two registration trial of amdizalisib, its...

Hutchmed signs drug licensing deal with Takeda for sales outside China
23 Jan 2023

Hutchmed signs drug licensing deal with Takeda for sales outside China

(Alliance News) - Hutchmed (China) Ltd on Monday said it has signed an licensing agreement with Takeda Pharmaceutical Co Ltd for the Japanese company ...